# BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

> **NCT06644443** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shenzhen University General Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **BIOLOGICAL:** BCMA-GPRC5D CAR-T cells

## Key facts

- **NCT ID:** NCT06644443
- **Lead sponsor:** Shenzhen University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-15
- **Primary completion:** 2025-07-14
- **Final completion:** 2026-07-14
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06644443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06644443, "BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06644443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*